


Portal: Cell Engineering Simplified

High Throughput, Scalable Mechanoporation

Portal uses mechanical deformation to deliver virtually any cargo to diverse cell types while maintaining cell health. It has the potential for transformational impact across fields from drug discovery to bed-side cell therapies



CEO: Armon Sharei, PhD


Former Founder and CEO of SQZ Biotech (NYSE: SQZ). Led over \$300M in equity financing, IPO, and \$1B+ Roche partnership. MIT PhD (Chemical Engineering), Harvard Medical School Postdoc (Immunology)

COO: Alec Barclay

Former COO of T2Biosystems. Former Sr. R&D leader at Becton Dickinson and Siemens. 5 FDA cleared devices, 13 assays, 6 RUO/CE devices. Rochester Institute of Technology (Mechanical Engineering)

POWERED BY PORTAL

Workflows at Every Scale




2023 Founded 50+ Partnerships 10+ Big Pharma



Next-Gen Cell Engineering


By enabling delivery of multiple cargos simultaneously, Portal could underpin many novel cell therapies



LIBRARIES BY PORTAL


Portal is developing modularized mixtures of RNA to program various cell functions without any genomic changes to the cell

Multiplexed Delivery: CRISPR RNP, mRNA, and Dextran to T Cells



Drug Discovery and Cell Analytics



By simplifying delivery of impermeable compounds and probes, Portal could enable new insights in drug discovery




Macrocyclic Peptides in HEK293

Macrocycle Delivery

Boost



Delivery of DELs in iPSCs




Portal Galaxy: Enabling High Throughput Screening with Integration to Opentrons Flex™



Galaxy Instrument Supports Manual Use or Liquid Handler Integration




The Galaxy Enables High Throughput Screening by Automated Dispensing into plates pre-loaded with cargo



Reliable Automated Solution



- The Portal Galaxy system seamlessly integrates with the Opentrons Flex™ system, increasing throughput, reducing manual effort and minimizing user error
- Cargoes are pre-plated in wells, and the Galaxy device mechanoporates cells, preparing them for the liquid handler
- Cells are pipetted into wells with cargo while the cell membrane remains open, ensuring efficient material delivery



Delivering Promega's LgBiT Reagents for Intracellular Protein Detection



- Successful delivery of LgBiT protein demonstrating potential for intracellular measurements of protein levels
- Addition of degraders demonstrates reduction in protein signal from live cell assays



Delivering Promega Reagents for NanoBRET Intracellular Target Engagement Assays

- HeLa cells transfected with NanoLuc-Src construct were treated with Src kinase inhibitors (Ponatinib or Bosutinib)
- Impermeable kinase tracer was mechanoporated into the cells
- Decrease in BRET ratio demonstrates reduction in intracellular kinase activity following inhibition

Ponatinib-treated NanoLuc-Src cells Bosutinib-treated NanoLuc-Src cells



• No Boost • Boost